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Abstract
Familial adenomatous polyposis (FAP) and MUTYH-associated polyposis (MAP) are inherited disorders associated
with multiple colorectal adenomas that lead to a very high risk of colorectal cancer. The somatic mutations
that drive adenoma development in these conditions have not been investigated comprehensively. In this study
we performed analysis of paired colorectal adenoma and normal tissue DNA from individuals with FAP or MAP,
sequencing 14 adenoma whole exomes (eight MAP, six FAP), 55 adenoma targeted exomes (33 MAP, 22 FAP)
and germline DNA from each patient, and a further 63 adenomas by capillary sequencing (41 FAP, 22 MAP).
With these data we examined the profile of mutated genes, the mutational signatures and the somatic mutation
rates, observing significant diversity in the constellations of mutated driver genes in different adenomas, and
loss-of-function mutations in WTX (9%; p< 9.99e-06), a gene implicated in regulation of the WNT pathway
and p53 acetylation. These data extend our understanding of the early events in colorectal tumourigenesis in the
polyposis syndromes.
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Over the last three decades there has been a dramatic
improvement in our understanding of the genetic basis
of germline susceptibility to colorectal cancer (CRC)
[1]. This began with the identification of the adenoma-
tous polyposis coli gene (APC) [2], in which germline
mutations cause familial adenomatous polyposis (FAP),
followed by the discovery of other genes such asMSH2
in Lynch syndrome [3] andmutY homologue (MUTYH )
inMUTYH-associated polyposis (MAP) [4] (also called
MYH-associated polyposis). Germline variants in the
genes LKB1, SMAD4, GREM1, PTEN, BMPR1A and
AXIN2 have also been implicated in predisposition to
colorectal cancer and highlight a role for many path-
ways in tumourigenesis of the colon [5]. More recently,
germline variants in the exonuclease domains of the
polymerase-ε catalytic subunit gene (POLE) and in the
DNA polymerase delta catalytic subunit (POLD1) gene
have been linked to colorectal adenoma and carcinoma
development [6]. Variants in POLE and POLD1 dra-
matically increase the somatic mutation rate, result-
ing in C:G→T:A somatic base changes [7]. While
the majority of colorectal cancers are sporadic, vari-
ants in the above-mentioned genes, and in several other
high-penetrance susceptibility genes including MLH1,
MSH6 and PMS2, collectively account for around 5% of
all cases [5]. While colorectal cancer is a common end-
point of germline variants in these genes, they initiate
tumourigenesis in different ways, meaning that the land-
scape of somatic mutations, the genes that are mutated
and the paths to malignancy, are likely to differ. As a
corollary, the multiplicity of tumours in patients with
germlinemutations in these genes differ and clinical out-
comes and responses to therapy can vary, suggesting
a complex interplay between the germline genetics of
each patient and the somatic landscape of adenomas
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and tumours that develop within the bowel [8]. Despite
major initiatives to analyse sporadic colorectal cancers
[9], little is known about the somatic landscape of
tumours from patients with hereditary forms of the dis-
ease. Here we set out to profile somatic mutations in
pre-malignant adenomas in two hereditary colon cancer
syndromes, FAP and MAP.
In FAP, adenomas may develop following somatic
inactivation of the wild-type allele of APC, an event
that is thought to be among the earliest somatic changes
occurring during tumourigenesis in these patients [10].
APC normally binds to GSK3β as part of a com-
plex called the ‘destruction complex’ which regulates
β-catenin stability, and hence the output of the WNT
pathway [11]. Loss or attenuation of the activities of
the destruction complex results in elevated levels of
β-catenin and of downstream effectors such as CCND1,
AXIN2 and BIRC5 [12]. These proteins participate
in the cell cycle, growth and regulation of cell death,
respectively. The location of the germline mutation
in APC in a FAP patient and the mode by which the
wild-type allele of the gene is inactivated during ade-
nomagenesis influence the degree to which the WNT
pathway is activated [13]. The level of WNT pathway
activation influences the multiplicity of intestinal poly-
posis and the growth of the adenomas that form, and is
described by the ‘just-right hypothesis’, which suggests
that adenomas aim to have sufficient WNT activation
to drive cell growth without tipping cells into apoptosis
or evoking cell death [14]. Fine-tuning of the WNT
pathway is thus central to colorectal tumourigenesis
[15]. MutY homologue (MUTYH) is a DNA glycosy-
lase that removes adenines mis-incorporated opposite
8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) [16].
Patients with MAP carry bi-allelic loss-of-function
mutations in the MUTYH gene, which in targeted
sequencing studies of adenomas was found to manifest
as an increase in somatic G:C→T:A mutations at the
APC locus [17]. Loss of MUTYH by itself is not onco-
genic, akin to some other colorectal cancer syndromes,
such as Lynch syndrome. With the exception of the
aforementioned mutations in APC, transversions in
RAS resulting in the generation of a G12C amino acid
change are the only other established somatic events
in MUTYH-driven tumourigenesis. The landscape of
somatic changes, the rate of somatic mutation and the
genes that are mutated in this disease are unknown.
Several studies have used next-generation sequencing
of human colorectal cancers to survey their somatic
mutational landscape. The Cancer Genome Atlas
(TCGA) characterized the genomes of 276 sporadic
colorectal cancers, focusing almost exclusively on inva-
sive cancers and metastatic tumours [9]. Other studies
have analysed the exomes of microsatellite-instable
(MSI) primary cancers [18], while Nikolaev et al
[19] performed a detailed and comprehensive analysis
of 24 sporadic adenomas, revealing a signature of
deamination (C→T at CpG sites), suggesting a role
for replication stress in mutational acquisition. Here we
focus on the early evolution of adenomas fromMAP and
FAP patients and investigate the somatic mutation rate
and the pattern of mutation. We also identify mutated
driver genes, including truncating mutations in WTX
(also known as FAM123B and AMER1).
Materials and methods
Tumour collection
Ethical approval and written informed consent from
each participant was obtained under UK NHS Research
Ethics Committee approvals 02/09/22 and 12/WA/0079.
Adenomas were harvested at colectomy or polypectomy
from the colorectum of patients with confirmed germline
mutations in APC or MUTYH. Larger adenomas were
halved longitudinally, with one part being snap-frozen
in liquid nitrogen and the other formalin-fixed for
histopathology. Smaller lesions were snap-frozen and
histopathology performed using a small sample cut
from the frozen material. A description of the germline
mutations carried by all patients and a summary of
their clinical histories is available in Table S1 (see
supplementary material). Three sets of adenomas
were analysed, using either whole-exome sequencing,
targeted-exome sequencing or capillary sequencing of
WTX, as described below. Histopathological analysis of
adenomas was performed by a clinical gastrointestinal
histopathologist (GTW). A summary of the pathology
reports is provided in Table S2 (see supplementary
material). DNA was extracted using the Qiagen DNeasy
Kit. Lesions selected for analysis were of similar
(sub-cm) size, with most showing low-grade dysplasia.
Whole-exome and targeted-exome sequencing
Whole-exome sequencing was performed using the Agi-
lent whole-exome capture kit (SureSelectXTHuman All
Exon 50Mb), as described previously [20]. Captured
material was indexed and sequenced on the Illumina
platform at the Wellcome Trust Sanger Institute. Tar-
geted capture sequencing was performed using baits
designed against the genes APC, WTX/FAM123B,
ATRNL1, BCL9L, BRCA1, BRCA2, CXCR5, DMD,
FBXW7, GPR112, HUWE1, KMT2C/MLL3, NF1,
PTEN, SLFN5, SMAD4, SORCS1, TP53, UBR2 and
ZNF37A, selected for sequencing on the basis of
being recurrently mutated, or truncated, in the unfil-
tered whole-exome sequencing data; these genes are
also enriched for non-silent mutations in the genome
sequencing of sporadic CRC [9]. A breakdown of
the sequencing metrics for each sample is provided
in Figure S1 (see supplementary material). We col-
lected and whole-exome sequenced 14 adenomas (eight
MAP and six FAP) from two MAP patients and two
FAP patients, and corresponding germline control
DNA for each patient (Figure 1; see also supplemen-
tary material, Figure S1, Table S2). In a similar way,
22 FAP and 33 MAP adenomas and corresponding
blood leukocyte DNA from three FAP and four MAP
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patients were sequenced using the targeted bait set (see
supplementary material, Table S2). DNA from all of
the adenomas and corresponding leukocyte controls
was available for follow-up genotyping/validation.
Seven cases that were whole-exome sequenced were
also targeted-exome sequenced (four FAP and three
MAP) to compare these platforms (see supplementary
material, Table S2). Table 1 provides a summary of the
sequenced samples.
Somatic single nucleotide variant calling
DNA sequence data from paired adenoma/normal
constitutional DNA samples were presented to the
Cake pipeline, which uses the somatic variant callers
Bambino, CaVEMan, SAMtools mpileup and VarScan2
[21]. As described previously [21], we used a somatic
caller merging approach to identify somatic variants,
selecting only those detected using three or more of
these algorithms for further analysis. We have previ-
ously shown that this approach increases the sensitivity
and specificity of variant detection [21]. These calls
were further filtered using modules such as the single
nucleotide polymorphisms (SNPs) filter, excluding
1000 Genomes Project phase 1 variants with minor
allele frequencies greater than 0.01 (> 0.01), and by
standard variant filtering.
Variant validation by Sequenom
We attempted to validate all non-silent somatic variant
calls from both the targeted- and whole-exome sequenc-
ing experiments using the Sequenomplatform. Both nor-
mal tissue and adenoma DNA samples were analysed as
described previously [22].
Capillary sequencing of WTX and KRAS
WTX was one of several genes found to carry truncating
mutations and was capillary sequenced in a larger panel
of adenomas (41 FAP and 22 MAP; see supplementary
material, Table S2) to extend the data collected from the
whole-exome and targeted-exome sequencing experi-
ments. In brief, primers were designed against each exon
of the gene, amplicons were bidirectionally sequenced
and variants called using Mutation Surveyor Software,
followed by manual inspection. KRAS sequencing was
performed as described by Jones et al [23].
Mutation signature analysis
We interpreted the mutational catalogue of MAP
and FAP using validated variants called from the
whole-exome sequence data, and also the raw variant
calls made by the Cake pipeline. For this task we used
EMu, a probabilistic algorithm that infers the number of
mutational processes operative and their individual sig-
natures [24]. Mutations were mapped to the 96 possible
trinucleotide combinations, taking into account the pos-
sibility for each mutation to occur in the context of each
trinucleotide type within the human genome. As the
model underlying EMu assumes that the input samples
are independent, we further collapsed the mutation data
by patient and performed a patient-centric signature
analysis.
Statistical analysis of WTX mutations
To determine whether WTX was significantly enriched
for nonsense mutations, we used Monte Carlo simu-
lations. 100 000 iterations were generated, where six
nucleotide changes were randomly introduced into the
WTX sequence (six being the number of changes found
inWTX in the targeted sequencing experiment; five non-
sense and one synonymous), using the underlying base
change probability from TCGA data across all tumour
types. We then computed all possible outcomes for these
mutations from each iteration and compared these fre-
quencies to the frequency of truncating mutations found
in the targeted-exome analysis.
Results
Calling and validation of somatic variants
We attempted to validate all non-silent positions at
which a candidate somatic variant call had been made
from the whole (573) or targeted (45) exome data
using the Sequenom platform. To do this, we geno-
typed DNA from each adenoma and a matched normal
tissue or leukocyte control DNA sample. We success-
fully designed assays against 434/573 positions from the
whole-exome sequencing experiment and 42/45 posi-
tions from the targeted-exome sequencing experiment.
The overall validation rate for the 434 calls from the
whole-exome sequencing of the MAP/FAP polyps was
80.87% (351 successfully genotyped somatic SNVs).
The validation rate for the targeted-exome experiment
was 95.23% (40/42) (see supplementarymaterial, Tables
S3, S4).
The frequency and distribution of somatic
mutations in FAP and MAP adenoma exomes
Figure 1A shows the breakdown of Sequenom-validated
protein-changing or disruptive somatic variants by
adenoma and disease and their mutational class; mis-
sense, nonsense or essential splice site. Figure 1B shows
the breakdown of validated non-silent somatic variants
by mutational class, disease, tumour and patient. All
variant calls, including synonymous variants, are shown
in Figure S2A, and their mutational profile is shown in
Figure S2B (see supplementary material); variant val-
idation metrics are provided in Figure S3. Analysis of
the somatic mutational landscape of protein-changing
variants in this way revealed a mean somatic muta-
tional burden of 0.65 mutations/Mb in MAP adenomas
compared to 0.16/Mb in FAP adenomas (p< 0.014)
(Figure 1C). When using the raw output of the Cake
pipeline, there were 0.98 and 0.59 variants/Mb for
MAP and FAP, respectively (p< 0.06) (Figure 1D).
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Figure 1. Somatic mutation calls from adenomas from patients with MAP or FAP. (A) Validated protein-changing somatic mutation calls
fromMAP and FAP adenomas: missense, nonsense and splice site variants are shown. (B) Profile of the validated somatic calls for the variants
shown in (A): the type of nucleotide change is indicated by the colour of each bar for each patient; adenoma IDs for each patient are shown
on the y axis (for clinical details, see supplementary material, Tables S1, S2); horizontal white/grey bar denotes chromosomes (no mutations
were found on chromosome 21). (C) Box plots showing, per megabase (Mb), median and 25th and 75th percentiles of validated somatic
variant calls calculated from the data shown in (A). (D) Box plots showing, per megabase (Mb), median and 25th and 75th percentiles of
somatic variant calls made using the Cake pipeline [21]; p values represent the results of Student’s two-tailed t-test. The variant calls used
in Figure 1 are provided in Table S3.
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7 FAP 11







Total 14 55 63
Seven samples were sequenced by both whole-exome and targeted-exome
sequencing but are not shown here; details are available in Table S2 (see
supplementary material).
These findings suggest an increased mutational burden
resulting from loss of MUTYH activity in the range
of 1.5–4.0-fold, comparable to findings reported in a
recent study of lymphoblastoid cell lines established
from MAP patients [25]. Importantly, we observed a
significant increase (p< 0.012; Student’s two-tailed
t-test) in the proportion of truncating mutations found
in adenomas from MAP patients compared to those
from FAP patients (Figure 1A). This observation may
reflect the different profiles of chromosomal imbalances
in FAP and MAP adenomas [26], such that tumour
suppressor genes undergo allelic loss in FAP rather than
being disrupted by point mutations.
The mutational signatures of FAP and MAP
We determined the pattern and distribution of somatic
nucleotide changes found in the eight MAP and six
FAP adenomas that were whole-exome sequenced.
Using both validated variant calls (Figure 1) and the
output of the Cake pipeline (see supplementary mate-
rial, Figure S2, Table S3), we used EMu software to
discern mutational signatures as a way of identifying
mutational processes that may be operative. This anal-
ysis revealed strong statistical support [Δ Bayesian
information criterion (Δ-BIC) score >171] for two
distinct mutational processes, signatures A and B, when
all 573 variant positions were used (see supplementary
material, Figure S4). Analysis of validated calls assum-
ing that two signatures are present led to similar results
(Figure 2A). Both signatures include C→T mutations
at XpCpG sites, compatible with spontaneous deami-
nation, but signature A also included C→A mutations,
especially at TpCpX sites. The latter may result from
sequence motifs that have enhanced mutability. We
also used EMu to estimate the mutational composition
of the 14 individual adenomas with respect to the
two mutational processes (Figure 2B). Signature
A, which is composed primarily of C:G→A:T
transversions that are typically associated with the
failure to remove misincorporated adenines opposite
8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG), was
the dominant signature in MAP adenomas (Figure 2).
In contrast the dominant mutational signature in FAP
adenomas was signature B (Figure 2B).
Driver mutations in MAP and FAP adenomas
We used the 351 validated somatic protein changing
variants from exome sequencing (see supplementary
material, Table S3) to ask which genes are likely to be
driver genes in colorectal adenoma formation. Of the
six FAP adenomas, three had somatic nonsense variants
in APC, all falling into the β-catenin binding domains of
APC and distal to the germline APC mutation found in
these patients (Figure 3). Of the eight MAP adenomas,
five had bi-allelic nonsense APC mutations. Truncating
mutations were also validated in SCUBE2, RELN,
FBXW7, MLL3, WTX/FAM123B, OTUD7B and KPRP
across the MAP and FAP adenomas (see supplementary
material, Table S3). Two adenomas (Figure 3) were
found to carry truncating mutations in the attractin-like
1 (ATRNL1) gene. Known driver genes from the cancer
gene census in which we identified missense mutations
included MAP3K5 and NRAS (p.Q61K; Figure 3; see
also supplementary material, Table S3). Two adenomas
carried missense mutations in the phospholipase C,
γ2 gene (PLCG2), which is related to PLCG1 recently
described as a driver gene in angiosarcoma [27].We also
found three adenomas carrying protein-changing KRAS
mutations; MAP polyp 1B4S carried a p.G12C, while
FAP polyps 12A11S and 9A5S carried p.A146T and
p.G13D changes, respectively. All of these variants were
validated by capillary sequencing. We next designed
a custom capture bait set against genes identified as
carrying truncating mutations, or as being recurrently
mutated in the unfiltered whole-exome sequencing data
(see Materials and methods). Analysis of 55 adenomas
(33 MAP and 22 FAP) and corresponding control DNA
using this bait set yielded the Sequenom-validated
somatic mutations shown in Figure 4A. Overviews of
the somatic mutations called by the Cake pipeline, the
results of their validation by Sequenom genotyping and
their mutational profiles are shown in the supplementary
material (see supplementary material, Figure S5, Table
S4). Of particular note was the identification of truncat-
ing mutations in WTX and mutations in genes such as
TP53,FBXW7 andPTEN. FourMAP polyps were found
to carry canonical KRAS p.G12C mutations resulting
from a somatic G:C→T:A change; GGT→TGT, a
figure in accord with a previous report [23]. Several
adenomas that were whole-exome sequenced were
also targeted-exome sequenced (Table 1; see also sup-
plementary material, Tables S2, S4). Owing to the
extremely high depth of sequence coverage obtained in
the targeted-exome studies, we identified and validated
additional driver mutations not seen by whole-exome
sequencing (Figure 2; see also supplementary material,
Table S4).
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Figure 2. Mutational signatures in MAP and FAP. (A) The mutation spectra across 96 mutational channels (each representing a trinucleotide
context, as described previously [37]). (B) Mutational signature activity plot, indicating the proportion of somatic mutations found in
adenomas from MAP and FAP patients that can be attributed to either signature A or signature B; the validated positions in Table S3 (see
supplementary material) were used for this analysis
WTX mutations in FAP and MAP
During the targeted sequencing of 33 MAP and 22
FAP adenomas, we identified and validated five trun-
cating WTX mutations, all in MAP lesions, represent-
ing a statistically significant enrichment of truncating
mutations in this gene (p< 9.99e-06). WTX mutations
have been reported in advanced colorectal cancer, but
their role in early stages of colorectal tumourigenesis
is unknown. In order to determine whether there were
differences in the frequency or profile ofWTX mutations
between early MAP- and FAP-associated adenomas, we
employed capillary sequencing to screen the exons and
exon–intron boundaries of WTX in a further 22 MAP
and 41 FAP adenomas. We identified nine further trun-
cating mutations (including one frameshift mutation),
six in FAP adenomas and three in MAP adenomas, and
one missense mutation in a MAP adenoma (Figure 4B;
see also supplementary material, Table S5).
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Figure 3. Candidate driver genes in adenomas fromMAP and FAP patients. The most frequently mutated genes inMAP and FAP adenomas are
shown: red boxes, nonsense mutations; blue boxes, missense mutations; a number in a variant box indicates where multiple mutations of the
same class are found. KRAS mutational status, determined by capillary sequencing, is also shown; some of the adenomas were also sequenced
by targeted-exome sequencing (TES); ** TES, missense mutations; * TES, nonsense mutations (see supplementary material, Table S2).
All positions were validated by Sequenom genotyping of tumour and control DNA; grey indicates no mutation found
The 17 truncating mutations of WTX identified in the
different phases of our study are all likely to impact the
function of its β-catenin binding region (Figure 4B).
Although WTX is on the X chromosome, we identi-
fied mutations in adenomas from both male and female
patients.We did not observe somatic bi-allelic mutations
in adenomas from females, suggesting that Lyonization
may be responsible for loss ofWTX function.WTX was
originally identified as a gene involved in the devel-
opment of Wilms’ tumour of the kidney [28] and has
reported roles in the regulation of the WNT pathway,
TP53 and cell fate, and in the localization of the tumour
suppressor protein WT1 [29–31]. Germline truncating
mutations in WTX have also been linked to a sclerosing
skeletal dysplasia (OSCS; MIM300373) and are not
considered to be associated with an increased risk of
tumours, although relatively early-onset colorectal can-
cer occurred in one of 25 adult patients in the original
report [32]. Mass-spectrometry studies have revealed
that WTX forms a complex with β-catenin, AXIN1,
β-transducin repeat-containing protein 2 (β-TrCP2)
and adenomatous polyposis coli (APC) to promote
the ubiquitination and degradation of β-catenin [33].
Knockdown experiments have shown WTX to be a neg-
ative regulator of theWNT pathway [33]; thus, mutation
of WTX may result in activation of this pathway and
the promotion of tumourigenesis. Figure 5 shows the
location of the somatic APC mutations identified in
each adenoma and their WTX mutational status. The
majority of the APC mutations found in adenomas with
WTX mutations fell into the β-catenin or mutator cluster
region (MCR), potentially resulting in impaired forma-
tion of the destruction complex, rather than its complete
loss [34], a scenario that may allow further modulation
of β-catenin signalling via changes in WTX expression.
Discussion
In this study we explored the somatic mutational
landscape of early-stage premalignant adenomas from
patients with germline mutations in APC and MUTYH
as a first step towards defining the catalogue of mutated
genes. This task is essential for identifying which
sets of mutations are most likely to lead adenomas to
progress to colorectal cancer. We revealed that MAP
adenomas have approximately two to four times the
number of coding region somatic mutations when com-
pared to FAP adenomas, and that these mutations are
overwhelmingly G:C→T:A mutations, in keeping with
the expected signature associated with MUTYH loss.
This observation confirms, for the first time, the expec-
tation that deficiency of MUTYH leads to a mutator
phenotype in colorectal tumours, and is consistent with
the observation of substantial colorectal cancer risk in
MAP, even in the absence of dense polyposis [35]. We
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Figure 4. WTX is a driver gene in adenomas in MAP and FAP. (A) The validated somatic mutations identified by targeted resequencing
of 33 MAP and 22 FAP adenomas are shown (see supplementary material, Table S4): red, nonsense somatic mutations; blue, missense
variants; green, essential splice site variants; KRAS mutations, which were assessed by capillary sequencing, are also shown; grey indicates
no mutation found. (B) Somatic variants identified in WTX by whole- and targeted-exome sequencing (bottom) and capillary sequencing
(top): the protein domains and positions are derived from Ensembl (ENST00000330258); NLS, nuclear localization signal; AA, acidic region;
CC, coiled-coil domain; PR, proline-rich region; BD, binding domain
find significant complexity in the patterns of mutated
genes, such that, with the exception of APC, KRAS and
WTX mutations, few adenomas have the same set of
mutated driver genes, a novel observation that may have
implications for the definition of high-risk adenomas in
the era of molecular pathology.
In FAP and MAP we found that 50% of tumours
carried somatic APC mutations (in the whole- and
targeted-exome experiments combined). Notably, the
frequency of bi-allelic mutations was found to differ
between our whole-exome and targeted-exome stud-
ies, despite an identical ascertainment of samples. In
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Figure 5. Germline and somatic APC mutations and somaticWTX mutational status. Predicted consequences of germline and somatic APC
mutations found in adenomas from FAP and MAP patients are shown. Colour-coded circles indicate mutation type. Ensembl APC protein
isoform ENST00000257430 and colour coded protein domains are shown: FAP, patients 5–8; MAP, patients 1, 2 and 4; mutations are
colour-coded by patient; arrows, lesions also carrying truncating WTX mutations identified by next-generation sequencing (see Figures 2,
4). Where an adenoma was found to carry bi-allelic APC mutations, we indicated the presence of a truncatingWTX mutation against both
mutations. We sequenced and validated somatic APC mutations in two adenomas from patient 2 that resulted in an amino acid change,
p.S1503 *. Both of these adenomas also carried truncating somatic WTX mutations (at positions p.E411X and p.E558X)
those lesions in which we did not find loss-of-function
mutations in APC it is possible that the gene is dis-
rupted by an imbalance of chromosome 5 [26] or by
copy number neutral changes at the APC locus [36].
The number of APC mutations we observed here was
slightly lower than estimates from the TCGA, who
report frequencies of 60–80% for hypermutated and
non-hypermutated cancers, respectively, and probably
reflects the difficulties of identifying somatic muta-
tions in lesions with low tumour cellularity. Intriguingly,
across all protein-coding geneswe observed a significant
enrichment for truncating mutations in MAP adenomas
compared to FAP (p< 0.012).We also observed a signif-
icant (p< 9.99e-06) incidence of truncatingWTX muta-
tions, with only APC being more frequently mutated.
Our study demonstrated that in patients with MAP or
FAP diverse molecular mechanisms are operational,
even at early stages of colorectal tumourigenesis. This
suggests that medical therapies for these disorders may
be most effective if they target the initiating events of
tumourigenesis prior to the development of mutationally
diverse adenomas.
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SUPPLEMENTARY MATERIAL ON THE INTERNET
The following supplementary material may be found in the online version of this article:
Figure S1. Sequencing metrics for the sequencing of adenomas and matched normal tissue samples from patients with MAP or FAP
Figure S2. Somatic variant calls made by the Cake pipeline from MAP and FAP cases
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Figure S3. Results of Sequenom validation experiments of somatic variant calls made using Cake against adenoma/matched normal tissue pairs from
MAP and FAP cases
Figure S4. Mutational signatures in MAP and FAP using all 573 calls made by the Cake pipeline
Figure S5. Results of targeted sequencing of adenoma/matched normal tissue pairs from MAP and FAP patients
Table S1. A summary of the clinical details of each patient
Table S2. A summary of the samples sequenced as part of this study
Table S3. Whole-exome variant calls
Table S4. Targeted-exome variant calls
Table S5. Capillary sequencing ofWTX and variant calls
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